Stockscreener 앱 받기
0.10
488.24%
0.083
전일 마감가:
$0.017
열려 있는:
$0.1
하루 거래량:
66,709
Relative Volume:
32.54
시가총액:
$N/A
수익:
-
순이익/손실:
$149.05M
주가수익비율:
0.0504
EPS:
1.9846
순현금흐름:
$-6.05M
1주 성능:
+488.24%
1개월 성능:
+488.24%
6개월 성능:
+488.24%
1년 성능:
-96.95%
1일 변동 폭
$0.10
$0.105
1주일 범위
$0.10
$0.105
52주 변동 폭
$0.017
$0.105
갈레라 테라 Stock (GRTX) Company Profile
Compare GRTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.10 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
422.98 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.30 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
778.15 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
307.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
292.67 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
갈레라 테라 Stock (GRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-19 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2019-12-02 | 개시 | BTIG Research | Buy |
| 2019-12-02 | 개시 | BofA/Merrill | Buy |
| 2019-12-02 | 개시 | Citigroup | Buy |
| 2019-12-02 | 개시 | Credit Suisse | Neutral |
모두보기
갈레라 테라 주식(GRTX)의 최신 뉴스
Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN
Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan
Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo
Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT - Sahm
Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo
Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq
Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive
Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan
M&A Class Action Firm Investigating Galera Acquisition - National Today
Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today
Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan
Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan
Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan
Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus
Obsidian Therapeutics, Inc. agreed to acquire Galera Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com
Galera Therapeutics to merge with Obsidian in $350M deal - Investing.com
Galera Therapeutics, Obsidian Therapeutics Announce Merger and $350M Private Placement - citybiz
GRTX | GALERA THERAPEUTICS INC Insider Trading - Quiver Quantitative
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Bluefield Daily Telegraph
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - ChartMill
Cell therapy biotech Obsidian leverages Galera reverse merger to go public - Fierce Biotech
Galera Therapeutics, Obsidian Therapeutics enter merger agreement - TipRanks
Galera Announces Obsidian Merger and $350M Financing - TipRanks
Galera Therapeutics (GRTX) to combine with Obsidian after $350M PIPE financing - Stock Titan
Galera Therapeutics to Merge With Obsidian; Secures $350 Million PIPE and Sets CVR for Legacy Assets - TradingView
Obsidian–Galera (OTC: GRTX) merger adds $350M PIPE to fund OBX-115 - Stock Titan
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Weekly Voice
GALERA THERAPEUTICS INCCO AND OBSIDIAN TO MERGE IN ALL-STOCK DEAL - Moomoo
[PRE 14A] Galera Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Nancy T. Chang Discloses Investment at Galera Therapeutics with 5.9% Stake - TradingView
Director grows Galera (NASDAQ: GRTX) stake via private placement and merger - Stock Titan
Galera Therapeutics, Inc. Files Form 8-K: Company Information, Stock Symbol GRTX, and No Exchange Listing as of April 2026 - Minichart
Galera Therapeutics Announces Share Conversions and Warrant Exercise - TipRanks
Galera Therapeutics (GRTX) director IRA converts 5.34M preferred-linked shares - Stock Titan
[Form 4] Galera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Preferred conversion and warrant exercise reshape Galera (GRTX) common stock - Stock Titan
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary - Business Wire
Galera Sets Deadlines for 2026 Combined Annual Meeting - The Globe and Mail
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
갈레라 테라 (GRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.57%
자본화:
|
볼륨(24시간):